Literature DB >> 11770392

Relationship between systemic corticosteroids and osteonecrosis.

K L Gebhard1, H I Maibach.   

Abstract

Numerous reports describe osteonecrosis after oral corticosteroid therapy. It is still uncertain if corticosteroid treatment alone or in combination with other factors leads to the development of this condition. The literature presents controversial clinical and experimental data. The most affected site for osteonecrosis is the femoral head and therefore our considerations are concentrated at this site. Oral corticosteroids are commonly used in dermatology, especially in the treatment of connective tissue diseases and hypersensitive diseases. This clinical review evaluates the relationship between and the onset of femoral head necrosis. Although osteonecrosis of the femoral head can be caused by various conditions such as trauma, excess alcohol and hemoglobinopathies, studies indicate that treatment with corticosteroids is the most common cause of the condition. There is some controversy on the role of underlying disease and total corticosteroid dose administered, in the development of osteonecrosis of the femoral head. MRI scans are used to establish an early diagnosis. There are several surgical and nonsurgical options for disease management, dependent on the stage of disease, the age of the patient and other risk factors. In general, the risk for osteonecrosis is considered to be low under oral corticosteroid therapy. So far, no data can establish a direct relationship, but data still strongly suggest an existing cause and effect relationship. Further investigations are necessary for example, a large controlled prospective long-term study, to further refine an association between the corticosteroid dose, the duration of treatment and other risk factors. Dermatologists who prescribe oral corticosteroids, should always be aware of the potential risk of avascular femoral head necrosis and the patients should be informed about this severe complication of oral coricosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11770392     DOI: 10.2165/00128071-200102060-00004

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  14 in total

Review 1.  Drug dosage in the elderly: dermatological drugs.

Authors:  Anna Flammiger; Howard Maibach
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Osteonecrosis of the Hip: A Primer.

Authors:  Michelle J Lespasio; Nipun Sodhi; Michael A Mont
Journal:  Perm J       Date:  2019

3.  Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

Authors:  Salvatore Ruggiero; Julie Gralow; Robert E Marx; Ana O Hoff; Mark M Schubert; Joseph M Huryn; Bela Toth; Kathryn Damato; Vicente Valero
Journal:  J Oncol Pract       Date:  2006-01       Impact factor: 3.840

Review 4.  Rheumatologic manifestations of benign and malignant haematological disorders.

Authors:  Vinod Ravindran; Parameswaran Anoop
Journal:  Clin Rheumatol       Date:  2011-06-23       Impact factor: 2.980

5.  11β-hydroxysteroid dehydrogenases as targets in the treatment of steroid-associated femoral head necrosis using antler extract.

Authors:  Ribusurong Pu; Hao Peng
Journal:  Exp Ther Med       Date:  2017-11-07       Impact factor: 2.447

6.  Multimodality treatment of a complex series of parallel pathologies in a 16-year-old male that ultimately leads to bilateral hip arthroplasty surgery: A case report.

Authors:  Emmet Cullen; John Quinlan; Esmond Fogarty; Peter Keogh
Journal:  Int J Surg Case Rep       Date:  2012-05-03

7.  ACTH protects against glucocorticoid-induced osteonecrosis of bone.

Authors:  Mone Zaidi; Li Sun; Lisa J Robinson; Irina L Tourkova; Li Liu; Yujuan Wang; Ling-Ling Zhu; Xuan Liu; Jianhua Li; Yuanzhen Peng; Guozhe Yang; Xingming Shi; Alice Levine; Jameel Iqbal; Beatrice B Yaroslavskiy; Carlos Isales; Harry C Blair
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

Review 8.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

9.  Genetic association of a polymorphism of the cAMP-responsive element binding protein-binding protein with steroid-induced osteonecrosis after kidney transplantation.

Authors:  Kyoko Tamura; Shigeo Nakajima; Yoshio Hirota; Kenji A Takahashi; Mikihiro Fujioka; Toshikazu Kubo; Yoshinori Iwatani; Keiichi Ozono
Journal:  J Bone Miner Metab       Date:  2007-08-25       Impact factor: 2.626

10.  What is the pain source? A case report of a patient with low back pain and bilateral hip osteonecrosis.

Authors:  Amy L Minkalis; Robert D Vining
Journal:  J Can Chiropr Assoc       Date:  2015-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.